Core Viewpoint - Gilead Sciences-B (01672) shares rose nearly 9% in early trading, with a current price of HKD 16.45 and a trading volume of HKD 42.25 million, following a significant investment from the Government of Singapore Investment Corporation (GIC) [1][5]. Group 1 - GIC purchased approximately 64.12 million new shares of Gilead Sciences at an average price of HKD 12.18 per share, totaling around HKD 781 million, resulting in GIC holding a 6.42% stake in the company [1][5]. - The investment is part of Gilead Sciences' recent completion of a placement plan, where the company sold a total of 69.26 million shares, raising a net amount of approximately HKD 835 million [1][5]. - Gilead Sciences indicated that 90% of the funds raised will be allocated for the global Phase III clinical development of the oral small molecule GLP-1 receptor agonist ASC30, covering trial preparation, foundational work, and formal initiation; the remaining 10% will be used for operational funding [1][5].
歌礼制药-B早盘涨超8% 获GIC斥资7.81亿港元增持歌礼制药